Gilead Sciences Inc (GILD) - News Archive

Gilead Sciences, Inc., a leading biopharmaceutical company, recently acquired CymaBay Therapeutics, Inc. as part of their ongoing commitment to developing innovative treatment options for liver diseases. The company has...

Investigational Seladelpar Shows Promising Results in Liver Disease Progression and Itch Reduction in Primary Biliary Cholangitis PatientsGilead Sciences, Inc. (Nasdaq: GILD) recently announced interim results from the...

Investigational Seladelpar Shows Promise in Treating Liver Disease and Itching in Primary Biliary Cholangitis Gilead Sciences, Inc. recently released interim results from the ongoing ASSURE study, revealing significant...

Advances in CAR T-Cell Therapy and Cancer Treatment Highlighted by Kite at Major 2024 Conferences Kite s Presentations at EHA 2024 Emphasize Positive Patient Outcomes and CAR T-Cell Therapy DeliverySANTA MONICA, Calif....

Kite, a Gilead Company, and Arcellx have revealed significant developments in their collaborative anitocabtagene autoleucel (anito-cel) multiple myeloma program. This program marks the first investigation of BCMA CAR T...

REDWOOD CITY, Calif. & SANTA MONICA, Calif. - In an exciting development for the field of multiple myeloma treatment, Kite, a Gilead Company, and Arcellx, Inc. have announced significant progress in their partnership s...

Gilead Sciences and Kite Oncology Showcase Promising Advances in Cancer Treatment at ASCO 2024In a commitment to revolutionize cancer treatment, Gilead Sciences, Inc. and its subsidiary Kite presented a total of 18 abst...

FDA Approves Biktarvy Label Update to Include Safety and Efficacy Data for Pregnant Adults With HIVIn a recent announcement, Gilead Sciences, Inc. revealed that the U.S. Food and Drug Administration (FDA) has granted ap...

The U.S. Food and Drug Administration (FDA) has granted approval for an updated label for Biktarvy, a medication developed by Gilead Sciences, Inc. The label includes additional data that further demonstrates the safety...

Kite and Arcellx Strengthen Partnership, Expanding Potential for Advanced Multiple Myeloma TreatmentIn an exciting development within the biopharmaceutical industry, Kite, a subsidiary of Gilead Sciences, and Arcellx an...